secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001213900-24-091959
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q3 net revenue $11.5M; net loss narrows to $2.8M; DefenCath access at 60% of US clinics
--------------------------------------------------------------------------------

- Q3 2024 net revenue of $11.5M from DefenCath first full quarter; net loss $2.8M ($0.05/sh) vs $9.7M loss ($0.17/sh) in Q3 2023.
- Commercial agreements now cover ~60% of US outpatient dialysis centers; four of top five dialysis providers.
- Cash and short-term investments $46.0M as of Sep 30, 2024; sufficient for at least 12 months.
- Operating expenses $14.1M, up 34% YoY due to selling, marketing, G&A for launch.
- Clinical study protocol for TPN indication amendment to be submitted to FDA by mid-November; study start H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390024091959/0001213900-24-091959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390024091959/ea0219021-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-091959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer